Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that frequently affect older adults and often require prolonged use of Bruton tyrosine kinase inhibitor (BTKi) therapy in the relapsed or refractory (R/R) setting. Ibrutinib and acalabrutinib are both recommended BTKis...
Read MoreAcalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: a ‘real-world’ study of efficacy and safety at a tertiary academic medical center. In this retrospective study, researchers compared the efficacy and safety of acalabrutinib monotherapy and acalabrutinib plus obinutuzumab as first-line...
Read MoreReprinted with permission. Clin Exp Med. 2025;26(1):80.* by Aviwe Ntsethe and Bongani Brian Nkambule Dr. Ntsethe is with Department of Human Physiology, Nelson Mandela University, Gqeberha, South Africa. Dr. Nkambule is with School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health Sciences, University...
Read MoreHeterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL) Tian S, Wang H, Parikh SA, et al. Leuk Res. 2026;160:108133. Summary. In this study, researchers compared the genomic profiles of 5 patients with chronic lymphocytic leukemia (CLL) and 7 patients with Richter...
Read MoreResearch Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor ibrutinib, though effective, has been associated with cardiac toxicity, including atrial fibrillation, heart failure, and sudden death. Acalabrutinib, a second-generation, more selective...
Read MorePilot evaluation of optical genome mapping in chronic lymphocytic leukemia: complementing FISH analysis Erdem S, Bayrak Tokaç AG, Aday A, et al. BMC Cancer. 2025;25(1):1687. Summary. Researchers compared fluorescence in situ hybridization (FISH) and optical genome mapping (OGM) findings in 20 newly diagnosed or treatment-naïve...
Read MoreEHA 2025 Congress on June 12–15, 2025, in Milan, Italy. A real-world comparison of hypertension and cardiovascular adverse events with acalabrutinib vs. ibrutinib in patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic leukemia. Acalabrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, has demonstrated comparable...
Read More©2026 Oncology Matrix. All Rights Reserved.
